• If you are trying to figure out whether Madrigal Pharmaceuticals is priced attractively today, the starting point is understanding what the current share price really reflects.
• The stock most recently closed at US$513.72, with returns of 0.3% over 7 days, a 6.1% decline over 30 days, a 13.5% decline year to date, a 62.8% return over 1 year, a 67.7% return over 3 years, and a very large 5 year gain of 293.9%.
• These mixed short term and longer term moves have kept Madrigal on the radar of investors weighing both the price and the underlying business story. Recent coverage has focused on how the share price history and fundamentals line up, which provides context for thinking about what you are actually paying for today.
• On Simply Wall St's 6 point valuation checklist, Madrigal currently scores 4 out of 6. The rest of this article will walk through the key valuation approaches behind that score, before finishing with a way to assess value that can help tie all of these methods together.

Approach 1: Madrigal Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today to estimate what the whole business might be worth in current dollars.

For Madrigal Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of about $192.4 million. Analyst and extrapolated projections then move this to positive territory, with forecast free cash flow of $1,715.6 million by 2030. Simply Wall St uses analyst inputs for the nearer years and then extends the trend further out, all expressed in US$.

Adding up and discounting these projected cash flows gives an estimated intrinsic value of about $1,776.49 per share. Compared with the recent share price of $513.72, this DCF output suggests Madrigal trades at a discount of about 71.1%. Based on these assumptions, the model views the stock as significantly undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Madrigal Pharmaceuticals is undervalued by 71.1%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: Madrigal Pharmaceuticals Price vs Sales

For companies where earnings are not yet a steady guide, the P/S ratio can be a useful way to compare what investors are paying for each dollar of revenue. It is often applied to biotech businesses where near term profits may not fully reflect the commercial potential of approved or pipeline products.

Growth expectations and risk play a big part in what counts as a normal or fair P/S multiple. Higher expected revenue growth or lower perceived risk can justify a higher P/S, while slower growth or higher uncertainty tends to support a lower figure.

Madrigal Pharmaceuticals currently trades on a P/S of 12.30x, compared with the Biotechs industry average of 11.01x and a peer average of 30.32x. Simply Wall St also calculates a Fair Ratio of 14.78x. This Fair Ratio is a proprietary estimate of what Madrigal’s P/S might be given factors such as its growth profile, industry, profit margins, market value and company specific risks.

Because the Fair Ratio blends these company specific drivers, it can give a more tailored yardstick than a simple comparison with peers or the broad industry.

With the current 12.30x P/S sitting below the 14.78x Fair Ratio, the shares appear undervalued on this metric.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.

Upgrade Your Decision Making: Choose your Madrigal Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced as a simple tool on Simply Wall St’s Community page where you can connect Madrigal Pharmaceuticals’ story to your own forecast for future revenue, earnings and margins. You can then translate that into a Fair Value and compare it with the current share price to decide whether the stock looks attractive. Each Narrative updates automatically when new news or earnings arrive and allows very different viewpoints. For example, one cautious view ties to a Fair Value of about US$529 and uses more conservative earnings and margin assumptions. A more optimistic view supports a Fair Value closer to US$904 with higher growth and profitability expectations. These views are shown side by side so you can see which story best matches what you believe.

Do you think there's more to the story for Madrigal Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.